AstraZeneca finalises long-term Zoladex supply
December 23, 2005
AstraZeneca finalises long-term agreement with PHARMAC for cancer treatment Zoladex
Pharmaceutical company AstraZeneca New Zealand Ltd today announced that it had finalised an agreement with the Pharmaceutical Management Agency of New Zealand (PHARMAC) for the long-term supply of its prostate and breast cancer medicine Zoladex®.
The agreement assures New Zealand patients of fully funded access to both the 3.6mg and 10.8 mg dosages of the drug until the end of 2008. AstraZeneca withdrew Zoladex® after a disagreement with PHARMAC over the level of subsidy, but reached a verbal agreement with the agency to resupply the drug earlier this week.
“We are delighted to have a reached a final long-term agreement with PHARMAC that is commercially viable for us and will give patients and clinicians continued fully subsidised access to Zoladex®, “ said AstraZeneca New Zealand General Manager Lance Gravatt.